Middletown Life

Author: TORREY PINES INVESTMENT

Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology

November 7, 2025
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

November 1, 2025
ChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer

November 1, 2025
Brenig Therapeutics Names Megan McGill as Chief Executive Officer

November 1, 2025